Literature DB >> 19579026

Abatacept as an option therapy in difficult to treat psoriatic arthritis.

Francisco José Fernandes Vieira, Maria Roseli Monteiro Callado, Walber Pinto Vieira.   

Abstract

Psoriatic arthritis (PA) is an inflammatory arthritis associated with cutaneous psoriasis. Treatment consists of non-steroidal anti-inflammatory drugs, corticosteroids at low doses and disease-modifying anti-rheumatic drugs. We relate a case of PA that after the fault of the handlings convecionais to sick we opted for an empiric treatment with Abatacept, based on the current knowledge on the physiopathology of PA and its low hepatotoxicity found in an animal model.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19579026     DOI： 10.1007/s00296-009-1041-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  6 in total

Review 1.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

Review 2.  Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options.

Authors:  Anthony M Turkiewicz; Larry W Moreland
Journal:  Arthritis Rheum       Date:  2007-04

3.  Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases.

Authors:  H Baker; T J Ryan
Journal:  Br J Dermatol       Date:  1968-12       Impact factor: 9.302

4.  CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis.

Authors:  Yasuhiro Nakayama; Yukihiro Shimizu; Katsuharu Hirano; Kazumi Ebata; Masami Minemura; Akiharu Watanabe; Toshiro Sugiyama
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

Review 5.  Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.

Authors:  P Nash; D O Clegg
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 6.  Translating co-stimulation blockade into clinical practice.

Authors:  Rene Westhovens; Patrick Verschueren
Journal:  Arthritis Res Ther       Date:  2008-10-15       Impact factor: 5.156
  6 in total
  3 in total

Review 1.  New treatments for inflammatory rheumatic disease.

Authors:  Carlo Selmi; Elena Generali; Marco Massarotti; Gerolamo Bianchi; Carlo A Sciré
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study.

Authors:  Fernando Kemta Lekpa; Cécile Poulain; Daniel Wendling; Martin Soubrier; Michel De Bandt; Jean Marie Berthelot; Philippe Gaudin; Eric Toussirot; Philippe Goupille; Thao Pham; Jérémie Sellam; Rémy Bruckert; Muriel Paul; Valérie Farrenq; Pascal Claudepierre
Journal:  Arthritis Res Ther       Date:  2012-03-09       Impact factor: 5.156

Review 3.  Current treatment options for psoriatic arthritis: spotlight on abatacept.

Authors:  Francesco Ursini; Emilio Russo; Roberto De Giorgio; Giovambattista De Sarro; Salvatore D'Angelo
Journal:  Ther Clin Risk Manag       Date:  2018-06-06       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.